EMBRACE

 BRCA1 and BRCA2 / Posted 1 year ago

EMBRACE: Epidemiological study of BRCA1 and BRCA2 mutation carriers

This study collects information about people who have inherited faulty breast cancer genes.

A small number of men and women have inherited faulty genes which means that they at an increased risk of developing certain cancers. Two of these genes are called BRCA1 and BRCA2. When someone has a fault in these genes they are more likely to develop cancers of the breast, ovary or prostate.

The EMBRACE study, which stands for Epidemiological Study of Familial Breast Cancer, aims to create a register of families who have a fault in these genes. The people taking part will be asked to fill in a questionnaire and to give a small sample of blood, which will be looked at in a laboratory. With this information they hope to find out

  • How many people go on to develop cancer
  • What other factors may play a part in the development of cancer
  • How the cancer risk may be reduced

The findings of this study will help doctors in the future to decide the best way to manage someone who has these faulty genes.

  • Inclusion Criteria : Subjects are eligible if there is a faulty BRCA1 or BRCA2 gene in their family and:
    • They have had genetic testing for BRCA1 or BRCA2 or there are plans to test them for these faulty genes in the future or
    • They had genetic counselling and have been offered testing for these faulty genes, but have decided not to have the test
    • Women are still eligible even if they have had breast or ovarian cancer or have had prophylactic surgery.
  • Exclusion Criteria : Subjects who are not eligible are those: · under 18 years of age · who are unable to give informed consent · who at the local investigators discretion are not thought appropriate to participate
  • Study start date : 01/08/1998
  • Study end date : 31/01/2022
  • Wales-Based Study Contact : please speak to your clinician
  • Principal Investigator : Professor Douglas Easton

No post found